Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 20/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243575 | 0.93 | KCNJ1 (0.51) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL21243579 | 0.93 | KCNJ1 (0.51) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20168387 | 0.91 | KCNJ1 (0.52) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20168389 | 0.91 | KCNJ1 (0.52) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20168438 | 0.90 | KCNJ1 (0.52) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20168440 | 0.90 | KCNJ1 (0.52) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20574412 | 0.90 | KCNJ1 (0.47) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20574414 | 0.90 | KCNJ1 (0.47) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL21243449 | 0.89 | KCNJ1 (0.53) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL20168208 | 0.87 | KCNJ1 (0.49) | KCNJ1KCNH2ACHESSTR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | KCNB1, CACNA1E, GRK1 | KCNJ1 85/4885KCNH2 53/4885ACHE 3965/4885 |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | KCNB1, CACNA1E, GRK1 | KCNJ1 85/4885KCNH2 53/4885ACHE 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.